Dimethylamine

Dimethylamine

SCHEMBL6932652

CCn1c(NC(=O)c2ccc(C)cc2)nc2ccccc21.CNC

nearest known ligand 0.79

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.79
NPSR1 Q6W5P4 5/20 0.79
RAB9A P51151 4/20 0.79
TDP1 Q9NUW8 1/20 0.79
TSHR P16473 5/20 0.78
MEN1 O00255 5/20 0.78
KMT2A Q03164 5/20 0.78
HTT P42858 4/20 0.78
HPGD P15428 3/20 0.78
HSD17B10 Q99714 2/20 0.78
SMN1; SMN2 Q16637 2/20 0.78
RXFP1 Q9HBX9 2/20 0.71
NPC1 O15118 2/20 0.71
USP2 O75604 3/20 0.67
OPRK1 P41145 3/20 0.67
TP53 P04637 2/20 0.67
MAPK1 P28482 1/20 0.67
OPRM1 P35372 1/20 0.67
OPRD1 P41143 1/20 0.67
POLB P06746 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimethylamine SCHEMBL6930444 0.90 KDM4E (0.92) KDM4ENPSR1RAB9ATDP1TSHR
SCHEMBL3604861 0.84 IRAK4 (0.80) KDM4ENPSR1RAB9ATDP1TSHR
SCHEMBL6933206 0.83 KDM4E (0.71) KDM4ENPSR1RAB9ATDP1TSHR
SCHEMBL6932648 0.82 KDM4E (0.82) KDM4ENPSR1RAB9ATDP1TSHR
Dimethylamine SCHEMBL6929910 0.78 KDM4E (0.93) KDM4ENPSR1RAB9ATDP1TSHR
SCHEMBL11703846 0.77 KDM4E (1.00) KDM4ENPSR1RAB9ATDP1TSHR
SCHEMBL11702089 0.77 RAB9A (0.64) KDM4ENPSR1RAB9ATDP1TSHR
Diethylamine SCHEMBL6929894 0.76 IRAK4 (0.53) KDM4ENPSR1RAB9ATDP1TSHR
SCHEMBL25956610 0.75 IRAK4 (1.00) KDM4ENPSR1RAB9ATDP1IRAK4
SCHEMBL11702096 0.75 RAB9A (0.65) KDM4ENPSR1RAB9ATDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6660870-B1 Serotonergic compounds which possess agonist activity at 5-HT2 receptors effectively lower and control normal and elevated IOP and are useful for treating glaucoma ALCON, INC. (CH) 2003-12-09 US disclosed